Frédérique Larousserie

Université Paris Descartes, Lutetia Parisorum, Île-de-France, France

Are you Frédérique Larousserie?

Claim your profile

Publications (50)114.37 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Extra-abdominal desmoid tumors are rare, locally aggressive neoplasms without metastatic potential. There is no clear consensus regarding their optimal management. The disappointing results of current treatments and the ability of extra-abdominal desmoid tumors to spontaneously stabilize have increasingly drawn interest toward conservative management. The objective of this study was to evaluate a wait-and-see policy as a first-line management for extra-abdominal desmoid tumors. This two-center retrospective study involved fifty-five patients with a histologically proven extra-abdominal desmoid tumor. The primary outcome was the cumulative probability of dropping out from the wait-and-see policy. The wait-and-see policy included aggressive management of symptoms. We conducted a review of the relevant published series in which a watchful-waiting strategy was used. The cumulative probability of dropping out from the wait-and-see policy was 9.6% at the time of the last follow-up. Spontaneous arrest of tumor growth was noted for forty-seven patients (85%) over the course of the study. Half of the tumors were stabilized at one year, and a potential to increase beyond three years was a sporadic event (one case). Regrowth was found in two patients (4%). A wait-and-see policy is an effective front-line management for patients with primary or recurrent extra-abdominal desmoid tumor. These tumors tend to stabilize spontaneously, on average after one year of evolution, and the cumulative probability of the failure of a wait-and-see policy is approximately 10%. Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence.
    The Journal of Bone and Joint Surgery 04/2014; 96(8):631-8. · 3.23 Impact Factor
  • P. Anract, F. Larousserie, O. Mir, A. Feydy
    [Show abstract] [Hide abstract]
    ABSTRACT: Los condrosarcomas son tumores malignos primarios de estirpe condral. Se trata de un grupo heterogéneo de tumores que pueden caracterizarse por su localización en el hueso (central, o condrosarcoma convencional, o en la superficie del hueso, condrosarcoma propiamente dicho). Los tumores se distinguen por el aspecto histológico, además de la forma frecuente (donde existe diferenciación del tumor en cartílago hialino). Se observan condrosarcomas de células claras, desdiferenciados y mesenquimatosos. Además, se reconocen los formados a partir de una lesión cartilaginosa preexistente (osteocondroma o condroma), denominados «condrosarcomas secundarios». El condrosarcoma desarrollado sobre un osteocondroma también se conoce como «condrosarcoma periférico». Los condrosarcomas no son sensibles a la quimioterapia y son relativamente resistentes a la radioterapia. El tratamiento se basa en la resección quirúrgica. Estudios recientes de caracterización biológica permiten entrever posibilidades de tratamiento médico adyuvante.
    EMC - Aparato Locomotor. 01/2014; 47(1):1–14.
  • G. Riouallon, F. Larousserie, E. Pluot, P. Anract
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction Les myxofibrosarcomes superficiels sont des tumeurs conjonctives malignes, dont les récidives, extrêmement fréquentes, mettent en jeu le pronostic local et général. Même lorsque l’exérèse chirurgicale semble complète macroscopiquement, elle est très souvent microscopiquement contaminée. Le but de ce travail était d’évaluer la récidive en fonction des marges de résection et de comparer, quand cela était possible, la taille de la lésion évaluée cliniquement et macroscopiquement par l’anatomopathologiste. Patients et méthodes Il s’agit d’une série rétrospective monocentrique composée de 21 patients, d’un âge moyen de 67 ans, pris en charge pour un myxofibrosarcome superficiel. Le nombre, la date et la localisation des récidives ont été colligés pour chaque patient. Pour chaque récidive, le plus grand axe de la tumeur a été évalué cliniquement et à l’examen anatomopathologique. Résultats Cinquante-sept pour cent des patients ont présenté une récidive. Le nombre moyen de récidives était de 1,4 par patient (1 à 8). Les marges de résection étaient saines dans quatre cas, marginales dans deux cas et incomplètes pour les 15 autres patients avec des taux de récidives respectifs de 25, 50 et 67 %. La taille évaluée à l’examen clinique préopératoire (14 cas) était sous-estimée en moyenne de 2,4 cm par rapport à la taille évaluée par l’examen macroscopique anatomopathologique. La taille évaluée sur l’IRM préopératoire (5 cas) était également sous-estimée de 1,3 cm en moyenne. Conclusion Les myxofibrosarcomes superficiels sont des tumeurs difficiles à réséquer complètement d’emblée en raison de leur caractère infiltrant, souvent sous-estimé avant l’intervention. Leur traitement chirurgical nécessite des marges de résection beaucoup plus larges que ne le laissent prévoir l’évaluation clinique et l’IRM. En cas de résection incomplète, la reprise cicatricielle doit être faite systématiquement. Niveau de preuve IV. Étude rétrospective.
    Revue de Chirurgie Orthopédique et Traumatologique 06/2013; 99(4):390–395.
  • G Riouallon, F Larousserie, E Pluot, P Anract
    [Show abstract] [Hide abstract]
    ABSTRACT: INTRODUCTION: Superficial myxofibrosarcomas are malignant connective tissue tumors, whose very frequent recurrence influences the local and vital prognosis. Even when resection seems to be macroscopically complete it is very often microscopically contaminated. The aim of this study was to evaluate recurrence in relation to the surgical margins and to compare, when possible, tumor size, evaluated clinically and macroscopically by the pathologist. MATERIALS AND METHODS: This was a single center study of 21 patients, mean age 67 years old, treated for superficial myxofibrosarcoma. The number, date and location of recurrence were collected for each patient. A clinical and pathological measurement was made of the longest axis of the tumor in each case of recurrence. RESULTS: Fifty-seven percent of patients presented with recurrent tumors. The mean number of recurrences was 1.4 per patient (1-8). The surgical margins were wide in four cases, marginal in two cases and incomplete/intralesional in 15 other patients with a rate of recurrence of 25, 50 and 67% respectively. The size evaluated during the preoperative clinical examination (14 cases) was underestimated by a mean 2.4cm compared to the macroscopic pathology assessment. The preoperative size on MRI (5 cases) was also underestimated by a mean 1.3cm. CONCLUSION: Superficial myxofibrosarcomas are tumors that are difficult to resect completely because they are infiltrative, a feature that is often underestimated before surgery. Surgical treatment of this entity requires a much larger surgical margin than that suggested by the preoperative clinical and MRI evaluations. In case of incomplete resection, revision scar surgery should systematically be performed. LEVEL OF EVIDENCE: Level IV. Retrospective study.
    Orthopaedics & Traumatology Surgery & Research 04/2013; · 1.06 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: [This corrects the article on p. e75694 in vol. 8.].
    PLoS ONE 01/2013; 8(11). · 3.73 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Interleukin (IL)-27 is a cytokine of the IL-12 family that displays either immunostimulatory or immunosuppressive functions depending on the context. In various murine tumor models including melanoma models, ectopic expression of IL-27 has been shown to play an anti-tumoral role and to favor tumor regression. In this study, we investigated whether IL-27 might play a role in the development of melanoma in humans. We analyzed the in situ expression of IL-27 in melanocytic lesions (n = 82) representative of different stages of tumor progression. IL-27 expression was not observed in nevus (n = 8) nor in in situ melanoma (n = 9), but was detected in 28/46 (61%) cases of invasive cutaneous melanoma, notably in advanced stages (19/23 cases of stages 3 and 4). In most cases, the main source of IL-27 was tumor cells. Of note, when IL-27 was detected in primary cutaneous melanomas, its expression was maintained in metastatic lesions. These in situ data suggested that the immunosuppressive functions of IL-27 may dominate in human melanoma. Consistent with this hypothesis, we found that IL-27 could induce suppressive molecules such as PD-L1, and to a lesser extent IL-10, in melanoma cells, and that the in situ expression of IL-27 in melanoma correlated with those of PD-L1 and IL-10.
    PLoS ONE 01/2013; 8(10):e75694. · 3.73 Impact Factor
  • Annals of Oncology 03/2012; 23(3):807-9. · 7.38 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Alveolar soft part sarcoma is a rare malignancy usually considered resistant to conventional chemotherapy, but recent data suggest that the multikinase inhibitors sunitinib and cediranib could be active in this setting. A 90-year-old lady with alveolar soft part sarcoma of the leg and lung metastases was started on sunitinib 37.5 mg daily. The treatment was poorly tolerated with grade 3 hypertension and grade 3 thrombocytopenia, which persisted after dose reduction to 25 mg daily. The patient was subsequently started on bevacizumab 10 mg/kg every 2 weeks, resulting in a marked improvement in pain and a partial response on lung metastases for 16 months and ongoing. Agents targeting the vascular endothelial growth factor-signalling pathway seem to exert clinically relevant and prolonged activity against alveolar soft part sarcoma and deserve further evaluation in the treatment of this rare soft tissue sarcoma.
    Anti-cancer drugs 02/2012; 23(7):745-8. · 2.23 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We report the case of a voluminous tumor of the adrenal diagnosed in a young pregnant woman at 26(th) week of amenorrhea. Morphologically, a soft white tumor with haemorragic areas was observed, made of sheets of monomorphous, medium sized, spindle-shaped to polygonal, with high mitotic activity. Tumorous cells expressed cytokeratins AE1/AE3, EMA, and CD99 (expression of vimentin is not relevant). Contemplated diagnoses included poorly differentiated synovialosarcoma, sarcomatoid carcinoma and Ewing tumor. Thanks to molecular biology, showing the specific transcript of Ewing/peripheral primitive neuroectodermal tumor (pPNET) EWS/FLI1, the diagnosis of this atypical tumor in an unusual location was performed. Indeed, 75% of Ewing tumors involve bones (especially, the diaphysis of long bones) and 20 to 25% soft tissues. Primitive visceral involvement is rare; less than 10 cases of adrenal involvement have been reported. The hypothesis that Ewing cell's origin is a mesenchymal stem cell, which may derive from neural crest cell, could explain the uncommon adrenal involvement. Diagnosis of Ewing tumor is based on pathologic and molecular findings, especially in atypical cases.
    Annales de Pathologie 02/2011; 31(1):28-31. · 0.24 Impact Factor
  • Annales De Pathologie - ANN PATHOL. 01/2011; 31(5).
  • [Show abstract] [Hide abstract]
    ABSTRACT: Myositis ossificans circumscripta (MOC) is a rare benign neoplasm located in soft tissues that, most of the time, appears after a local trauma. The positive diagnosis of MOC may be challenging on CT or MRI findings. We report on an atypical case of a spontaneous nontraumatic MOC in a 54-year-old man, located in the longus supinatus muscle diagnosed with MRI and F-18 FDG PET/CT findings. Rarely described F-18 FDG PET/CT features in MOC are presented. Pattern of avid FDG focus on PET/CT, that may wrongly suggest osteosarcoma, is presented.
    Clinical nuclear medicine 01/2011; 36(1):40-2. · 3.92 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We report the case of a voluminous tumor of the adrenal diagnosed in a young pregnant woman at 26th week of amenorrhea. Morphologically, a soft white tumor with haemorragic areas was observed, made of sheets of monomorphous, medium sized, spindle-shaped to polygonal, with high mitotic activity. Tumorous cells expressed cytokeratins AE1/AE3, EMA, and CD99 (expression of vimentin is not relevant). Contemplated diagnoses included poorly differentiated synovialosarcoma, sarcomatoid carcinoma and Ewing tumor. Thanks to molecular biology, showing the specific transcript of Ewing/peripheral primitive neuroectodermal tumor (pPNET) EWS/FLI1, the diagnosis of this atypical tumor in an unusual location was performed. Indeed, 75% of Ewing tumors involve bones (especially, the diaphysis of long bones) and 20 to 25% soft tissues. Primitive visceral involvement is rare; less than 10 cases of adrenal involvement have been reported. The hypothesis that Ewing cell's origin is a mesenchymal stem cell, which may derive from neural crest cell, could explain the uncommon adrenal involvement. Diagnosis of Ewing tumor is based on pathologic and molecular findings, especially in atypical cases.
    Annales de Pathologie 01/2011; 31(1):28-31. · 0.24 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The distinction between Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL), two types of mature aggressive B-cell lymphomas that require distinct treatments, can be difficult because of forms showing features intermediate between DLBCL and BL (here called BL/DLBCL). They can be discriminated by the presence of c-myc translocations characteristic of BL. However, these are not exclusive of BL and when present in DLBCL are associated with lower survival. In this study, we show that Epstein-Barr virus-induced gene 3 (EBI3) is differentially expressed among BL and DLBCL. Analysis of gene expression data from 502 cases of aggressive mature B-cell lymphomas available on Gene Expression Omnibus and immunohistochemical analysis of 184 cases of BL, BL/DLBCL or DLBCL, showed that EBI3 was not expressed in EBV-positive or -negative BL cases, whereas it was expressed by over 30% of tumoral cells in nearly 80% of DLBCL cases, independently of their subtypes. In addition, we show that c-myc overexpression represses EBI3 expression, and that DLBCL or BL/DLBCL cases with c-myc translocations have lower expression of EBI3. Thus, EBI3 immunohistochemistry could be useful to discriminate BL from DLBCL, and to identify cases of BL/DLBCL or DLBCL with potential c-myc translocations.
    PLoS ONE 01/2011; 6(9):e24617. · 3.73 Impact Factor
  • Guillaume Riouallon, Frédérique Larousserie, Etienne Pluot, Philippe Anract
    Resuscitation 01/2011; 97(7). · 4.10 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Erdheim-Chester disease (ECD) pathophysiology remains largely unknown. Its treatment is not codified and usually disappointing. Interferon (IFN)-α therapy lacks efficacy for some life-threatening manifestations and has a poor tolerance profile. Because interleukin (IL)-1Ra synthesis is naturally induced after stimulation by IFN-α, we hypothesized that recombinant IL-1Ra (anakinra) might have some efficacy in ECD. We treated 2 patients who had poor tolerance or contraindication to IFN-α with anakinra as a rescue therapy and measured their serum C-reactive protein, IL-1β, IL-6, and monocytic membranous IL-1α (mIL-1α) levels before, under, and after therapy. Another untreated ECD patient and 5 healthy subjects were enrolled as controls. After treatment, fever and bone pains rapidly disappeared in both patients, as well as eyelid involvement in one patient. In addition, retroperitoneal fibrosis completely or partially regressed, and C-reactive protein, IL-6, and mIL-1α levels decreased to within the normal and control range. Beside injection-site reactions, no adverse event was reported. Therefore, our results support a central role of the IL-1 network, which seemed to be overstimulated in ECD. Its specific blockade using anakinra thereby opens new pathophysiology and therapeutic perspectives in ECD.
    Blood 11/2010; 116(20):4070-6. · 9.06 Impact Factor
  • Journal de Radiologie 11/2010; 91(11 Pt 1):1158-60. · 0.35 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To report the biopsy findings of osteoid osteoma (OO) and OO-mimicking lesions, assess their distinctive multidetector computed tomography (MDCT) features and evaluate treatment by radiofrequency ablation (RFA). In this multicentric retrospective study, 80 patients (54 male, 26 female, mean age 24.1 years, range 5-48) with presumed (clinical and MDCT features) OO were treated by percutaneous RFA between May 2002 and June 2009. Per-procedural biopsies were always performed. The following MDCT features were assessed: skeletal distribution and location within the bone, size, central calcification, surrounding osteosclerosis and periosteal reaction. Clinical success of RFA was evaluated. Histopathological diagnoses were: 54 inconclusive biopsies, 16 OO, 10 OO-mimicking lesions (5 chronic osteomyelitis, 3 chondroblastoma, 1 eosinophilic granuloma, 1 fibrous dysplasia). OO-mimicking lesions were significantly greater in size (p = 0.001) and presented non-significant trends towards medullary location (p = 0.246), moderate surrounding osteosclerosis (p = 0.189) and less periosteal reaction (p = 0.197), compared with OO. Primary success for ablation of OO-mimicking lesions was 100% at 1 month, 85.7% at 6 and 12 months, and 66.7% at 24 months. Secondary success was 100%. Larger size, medullary location, less surrounding osteosclerosis and periosteal reaction on MDCT may help differentiate OO-mimicking lesions from OO. OO-mimicking lesions are safely and successfully treated by RFA.
    European Radiology 05/2010; 20(10):2439-46. · 4.34 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Dedifferentiated chondrosarcomas are highly malignant tumors characterized by conventional low-grade chondrosarcoma with abrupt transition to foci that have dedifferentiated into a higher-grade noncartilaginous more aggressive sarcoma. The dedifferentiated component, an osteosarcoma or fibrosarcoma, determines the prognosis. Its identification is key for management. A diagnosis of dedifferentiated chondrosarcoma should be suggested by the presence of "tumoral dimorphism" with cartilaginous component and aggressive lytic component invading adjacent soft tissues.
    Journal de Radiologie 03/2010; 91(3 Pt 1):271-9. · 0.35 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the reliability and renal safety of an original schedule of high-dose methotrexate (HDMTX) administration with hyper-alkalinization, and without hyper-hydration. Patients with osteosarcoma received HDMTX (8-12 g/m(2)) as a 4-h infusion. Hypertonic 8.4% sodium bicarbonate was infused prior to HDMTX, then once daily for 3 days. Methotrexate serum concentrations were measured at hour 4 (Cmax), hour 24, hour 48, and hour 72. Urinary pH was measured on each miction. Serum creatinine was assessed on days 1, 3, and 8. Twenty-six patients (median age: 18 years, range: 15-25) received a total of 344 cycles of HDMTX, including 16 patients treated in an outpatient basis. Urinary pH remained constantly higher than 7.5 in all patients. Grade 1 creatininemia toxicity was observed in 31 cycles (9%), and grade 2 creatinine toxicity was observed in one patient. No episode of acute severe nephrotoxicity was observed. No significant worsening was observed in serum creatinine and calculated creatinine clearance from baseline to the end of therapy (P = 0.74). The main extra-renal toxicity was alkalinization-related hypokalemia from H48. No re-hospitalization was required. Hyper-alkalinization appears an efficient and reliable method to prevent the acute renal toxicity of HDMTX and allows its safe administration in the outpatient setting.
    Cancer Chemotherapy and Pharmacology 02/2010; 66(6):1059-63. · 2.80 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Dedifferentiated chondrosarcomas are highly malignant tumors characterized by conventional low-grade chondrosarcoma with abrupt transition to foci that have dedifferentiated into a higher-grade noncartilaginous more aggressive sarcoma. The dedifferentiated component, an osteosarcoma or fibrosarcoma, determines the prognosis. Its identification is key for management. A diagnosis of dedifferentiated chondrosarcoma should be suggested by the presence of “tumoral dimorphism” with cartilaginous component and aggressive lytic component invading adjacent soft tissues.
    Journal De Radiologie - J RADIOL. 01/2010; 91(3):271-279.

Publication Stats

379 Citations
114.37 Total Impact Points

Institutions

  • 2009–2014
    • Université Paris Descartes
      • Faculté de Médecine
      Lutetia Parisorum, Île-de-France, France
  • 2009–2013
    • Université René Descartes - Paris 5
      • • Faculté de Médecine
      • • Faculté de Médecine
      Lutetia Parisorum, Île-de-France, France
  • 2010
    • CHRU de Strasbourg
      Strasburg, Alsace, France
  • 2005–2007
    • French National Centre for Scientific Research
      Lutetia Parisorum, Île-de-France, France